Francis Collins via Getty Images

NIH cor­rals bio­phar­ma com­pa­nies, reg­u­la­tors and tri­al net­works to co­or­di­nate Covid-19 R&D

Fran­cis Collins’ grand plan to bring or­der to the chaot­ic rush for Covid-19 vac­cines and treat­ments is here.

The pub­lic-pri­vate part­ner­ship that the NIH di­rec­tor teased a few days ago will be known as AC­TIV or Ac­cel­er­at­ing COVID-19 Ther­a­peu­tic In­ter­ven­tions and Vac­cines. By com­pil­ing re­sources, lever­ag­ing ex­ist­ing net­works, lob­by­ing reg­u­la­tors and set­ting up a steer­ing com­mit­tee to pri­or­i­tize promis­ing can­di­dates, the goal is to gen­er­ate more com­pre­hen­sive da­ta quick­er.

“We want to do this in the most com­pelling sci­en­tif­ic way,” Collins said in a tele­brief­ing, where he echoed ear­li­er com­ments that he hopes to find 3 to 4 treat­ments that show ben­e­fit around June or Ju­ly.

Aside from gov­ern­ment agen­cies — the FDA and its Eu­ro­pean coun­ter­part, the HHS and the CDC — 16 bio­phar­ma com­pa­nies were al­so named to the group: Ab­b­Vie, Am­gen, As­traZeneca, Bris­tol My­ers Squibb, Evotec, Glax­o­SmithK­line, J&J, KSQ Ther­a­peu­tics, Eli Lil­ly, Mer­ck, No­var­tis, Pfiz­er, Roche, Sanofi, Take­da and Vir.

There are cur­rent­ly more than 400 clin­i­cal tri­als eval­u­at­ing po­ten­tial Covid-19 drugs and vac­cines, ac­cord­ing to clin­i­cal­tri­ — a num­ber that grows by the day. A work­ing group with­in AC­TIV will take all the data­bas­es cur­rent­ly out there, from Bio­Cen­tu­ry’s re­source cen­ter to the Milken Track­er and merge them to get a good idea of every­thing that’s out there, Collins said.

Then they will be­gin rank­ing all the can­di­dates and, when nec­es­sary, re­jig cur­rent arrange­ments:

A num­ber of tri­als, as you know, are un­der­way with hy­drox­y­chloro­quine and chloro­quine. One of the things that the group is try­ing to do is to get an in­ven­to­ry of ex­act­ly how many tri­als of what size and what sever­i­ty of pa­tients are there, be­cause it may well be that we al­ready have enough to in­for­ma­tion to be able to as­sess whether there’s ben­e­fit or not, in which case those tri­als might bet­ter be adapt­ed to some oth­er can­di­date ther­a­peu­tics. The remde­sivir tri­al which NIH is run­ning has al­ready en­rolled 800 par­tic­i­pants when it on­ly need­ed 500 to be pow­ered. One of the ques­tions is should that par­tic­u­lar tri­al net­work, al­ready ex­ist­ing, now be adapt­ed to try a dif­fer­ent ap­proach, a dif­fer­ent can­di­date ther­a­peu­tic, so that we can learn things as quick­ly as pos­si­ble.

Al­so part of the plan: de­sign­ing, launch­ing and shar­ing mas­ter pro­to­cols that use a sin­gle con­trol arm. It would pre­sum­ably be an ex­pan­sion of ACTT, the adap­tive tri­al that the NI­AID has al­ready launched with Gilead’s remde­sivir and Eli Lil­ly’s Olu­mi­ant. Ex­ist­ing NIH net­works that are pre­vi­ous­ly fo­cused on every­thing from HIV to or­gan trans­plants have al­so pledged to help.

While any com­pa­ny is still free to move on with their own ther­a­peu­tic can­di­dates, there may now be less room for them to do so. Be­tween all the play­ers in­volved in AC­TIV, Collins added, they will like­ly have con­trol of the ma­jor­i­ty of pub­lic and pri­vate clin­i­cal tri­al net­works.

For the 40-plus vac­cine pro­grams, the main fo­cus is on de­vel­op­ing as­says, con­sol­i­dat­ing da­ta on im­muno­log­i­cal re­spons­es and fig­ur­ing out sur­ro­gate end­points.

But it al­so goes be­yond what’s al­ready in the clin­ic, with man­dates to stan­dard­ize pre­clin­i­cal eval­u­a­tion and in­crease ac­cess to val­i­date an­i­mal mod­els, which tripped up re­searchers in the ear­ly days.

Like the FDA’s Coro­n­avirus Treat­ment Ac­cel­er­a­tion Pro­gram, it’s all in­tend­ed to find some­thing, any­thing, that can re­duce the dis­ease’s dev­as­tat­ing toll as the White House in­structs states to con­sid­er lift­ing move­ment re­stric­tions in May. In its days of ex­is­tence, crit­ics have lament­ed that CTAP has not lived up to its promise; it re­mains to be seen whether a “na­tion­al strat­e­gy” can speed things up on the ground.

“There’s a lot of re­sources al­ready de­vot­ed to this,” Collins said, cit­ing con­gres­sion­al fund­ing and the phar­ma part­ners’ com­mit­ments. ‘They need to be di­rect­ed in the best way.”

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.

As­traZeneca trum­pets the good da­ta they found for Tagris­so in an ad­ju­vant set­ting for NSCLC — but many of the ex­perts aren’t cheer­ing along

AstraZeneca is rolling out the big guns this evening to provide a salute to their ADAURA data on Tagrisso at ASCO.

Cancer R&D chief José Baselga calls the disease-free survival data for their drug in an adjuvant setting of early stage, epidermal growth factor receptor-mutated NSCLC patients following surgery “momentous.” Roy Herbst, the principal investigator out of Yale, calls it “transformative.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi CEO (Getty Images)

Sanofi CEO Paul Hud­son has $23B burn­ing a hole in his pock­et. And here are some hints on how he plans to spend that

Sanofi has reaped $11.1 billion after selling off a big chunk of its Regeneron stock at $515 a share. And now everyone on the M&A side of the business is focused on how CEO Paul Hudson plans to spend it.

After getting stung in France for some awkward politicking — suggesting the US was in the front of the line for Sanofi’s vaccines given American financial support for their work, versus little help from European powers — Hudson now has the much more popular task of managing a major cash cache to pull off something in the order of a big bolt-on. Or two.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.

David Chang, Allogene CEO (Jeff Rumans)

Head­ed to PhII: Al­lo­gene CEO David Chang com­pletes a pos­i­tive ear­ly snap­shot of their off-the-shelf CAR-T pi­o­neer

Allogene CEO David Chang has completed the upbeat first portrait of the biotech’s off-the-shelf CAR-T contender ALLO-501 at virtual ASCO today, keeping all eyes on a drug that will now try to go on to replace the first-wave personalized pioneers he helped create.

The overall response rate outlined in Allogene’s abstract for treatment-resistant patients with non-Hodgkin lymphoma slipped a little from the leadup, but if you narrow the patient profile to treatment-naïve patients — removing the 3 who had previous CAR-T therapy who didn’t respond, leaving 16 — the ORR lands at 75% with a 44% complete response rate. And 9 of the 12 responders remained in response at the data cutoff, offering a glimpse on durability that still has a long way to go before it can be completely nailed down.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.

The Avance Clinical leadership team: CEO Yvonne Lungershausen, Sandrien Louwaars - Director Business Development Operations, Gabriel Kremmidiotis - Chief Scientific Officer, Ben Edwards - Chief Strategy Officer

How Aus­tralia De­liv­ers Rapid Start-up and 43.5% Re­bate for Ear­ly Phase On­col­o­gy Tri­als

About Avance Clinical

Avance Clinical is an Australian owned Contract Research Organisation that has been providing high-quality clinical research services to the local and international drug development industry for 20 years. They specialise in working with biotech companies to execute Phase 1 and Phase 2 clinical trials to deliver high-quality outcomes fit for global regulatory standards.

As oncology sponsors look internationally to speed-up trials after unprecedented COVID-19 suspensions and delays, Australia, which has led the world in minimizing the pandemic’s impact, stands out as an attractive destination for early phase trials. This in combination with the streamlined regulatory system and the financial benefits including a very favourable exchange rate and the R & D cash rebate makes Australia the perfect location for accelerating biotech clinical programs.

Af­ter star­ring at ASH last fall, Gilead’s new Forty Sev­en crew col­ors in more promis­ing da­ta for ma­grolimab at AS­CO

We now know the full, early-stage story behind the drug that inspired Gilead CEO Dan O’Day’s recent $5 billion acquisition of Forty Seven.

Following up on their ASCO abstract from a couple of weeks ago, the team at Forty Seven is making their return appearance this week holding clearly promising early-stage data on their lead drug magrolimab as they ponder whether they should roll on a quest to obtain an accelerated approval.

Pablo Legorreta, founder and CEO of Royalty Pharma AG, speaks at the annual Milken Institute Global Conference in Beverly Hills, California (Patrick T. Fallon/Bloomberg via Getty Images)

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

Pablo Legorreta is one of the most influential players in biopharma you likely never heard of.

Over the last 24 years, Legorreta’s Royalty Pharma group has become, by its own reckoning, the biggest buyer of drug royalties in the world. The CEO and founder has bought up a stake in a lengthy list of the world’s biggest drug franchises, spending $18 billion in the process — $2.2 billion last year alone. And he’s become one of the best-paid execs in the industry, reaping $28 million from the cash flow last year while reserving 20% of the cash flow, less expenses, for himself.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.

Pfiz­er, Mer­ck KGaA ce­ment Baven­cio blad­der can­cer win with OS da­ta — while carv­ing an­oth­er niche in rare can­cer

Pfizer and Merck KGaA have detailed the Phase III data that inspired FDA regulators to designate Bavencio a “breakthrough” for first-line advanced bladder cancer and offered an early glance at how the PD-L1 can help patients with a rare gynecological cancer — carving out niches in the checkpoint space for itself after being shut out of numerous others.

In JAVELIN Bladder 100, Bavencio led to a 31% reduction in risk of death compared to standard care alone. It also extended median survival by more than seven months — a historic feat in this setting, according to investigators at Queen Mary University of London.

Sanofi brings in 4 new ex­ec­u­tives in con­tin­ued shake-up, as vac­cines and con­sumer health chief head out the door

In the middle of Sanofi’s multi-pronged race to develop a Covid-19 vaccine, David Loew, the head of their sprawling vaccines unit, is leaving – part of the final flurry of moves in the French giant’ months-long corporate shuffle that will give them new-look leadership under new CEO Paul Hudson.

The company also said today that Alan Main, the head of their consumer healthcare unit, is out, and they named 4 executives to fill new or newly vacated positions, 3 of whom come from both outside both Sanofi and from Pharma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 82,500+ biopharma pros reading Endpoints daily — and it's free.

Iron­wood, Ab­b­Vie kick de­layed-re­lease Linzess for­mu­la­tion to the curb af­ter tri­al fail­ure

The delayed-release formulation of Ironwood and Allergan’s bowel drug Linzess will not see the light of day.

The experimental drug, MD-7246, failed to help patients with abdominal pain associated with irritable bowel syndrome with diarrhea (IBS-D) in a mid-stage study, prompting the partners to abandon the therapy.

First approved in 2012, Linzess (known chemically as linaclotide) enhances the activity of the intestinal enzyme guanylate cyclase-C to increase the secretion of intestinal fluid and then transit through the intestinal tract, as well as reduce visceral pain, to relieve pain and constipation associated with IBS.